Related references
Note: Only part of the references are listed.MK2 is a therapeutic target for high-risk multiple myeloma
Chunyan Gu et al.
HAEMATOLOGICA (2021)
MK2 is a therapeutic target for high-risk multiple myeloma
Chunyan Gu et al.
HAEMATOLOGICA (2021)
RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma
Chunyan Gu et al.
LEUKEMIA (2021)
Kinome expression profiling to target new therapeutic avenues in multiple myeloma
Hugues de Boussac et al.
HAEMATOLOGICA (2020)
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer
Johanna C. Bendell et al.
INVESTIGATIONAL NEW DRUGS (2020)
Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage
Nicholas J. H. Warren et al.
ONCOGENE (2020)
Comprehensive profiling of circular RNA expressions reveals potential diagnostic and prognostic biomarkers in multiple myeloma
Fan Zhou et al.
BMC CANCER (2020)
Proteogenomic Characterization of Endometrial Carcinoma
Yongchao Dou et al.
CELL (2020)
Drug Targeting of Genomic Instability in Multiple Myeloma
Meral Beksac et al.
FRONTIERS IN GENETICS (2020)
Trifolirhizin induces autophagy-dependent apoptosis in colon cancer via AMPK/mTOR signaling
Dongdong Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway
Yashu Feng et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
CEP135 isoform dysregulation promotes centrosome amplification in breast cancer cells
Divya Ganapathi Sankaran et al.
MOLECULAR BIOLOGY OF THE CELL (2019)
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Elizabeth Ruth Plummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
Mengjie Guo et al.
FRONTIERS IN ONCOLOGY (2019)
Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer
Paul Dent
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis
Yibing Yang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis
Yibing Yang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells
Begona Canovas et al.
CANCER CELL (2018)
Detecting Chromosome Condensation Defects in Gulf War Illness Patients
Guo Liu et al.
CURRENT GENOMICS (2018)
Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma
Ryan A. Denu et al.
MOLECULAR CANCER RESEARCH (2018)
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Irene M. Ghobrial et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
Chunyan Gu et al.
BLOOD CANCER JOURNAL (2018)
Hierarchical assembly of centriole subdistal appendages via centrosome binding proteins CCDC120 and CCDC68
Ning Huang et al.
NATURE COMMUNICATIONS (2017)
Chromosomal instability and acquired drug resistance in multiple myeloma
Wang Wang et al.
ONCOTARGET (2017)
Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function
Federico Gulluni et al.
CANCER CELL (2017)
Evolutionary biology of high-risk multiple myeloma
Charlotte Pawlyn et al.
NATURE REVIEWS CANCER (2017)
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response
Yuhuan Zheng et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Dishevelled is a NEK2 kinase substrate controlling dynamics of centrosomal linker proteins
Igor Cervenka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response
Yuhuan Zheng et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Giada Bianchi et al.
BLOOD (2015)
A Synergistic Interaction between Chk1-and MK2 Inhibitors in KRAS-Mutant Cancer
Felix Dietlein et al.
CELL (2015)
Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement
Meletios A. Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tank binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis
Smitha Pillai et al.
NATURE COMMUNICATIONS (2015)
Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche
Michelle A. Lawson et al.
NATURE COMMUNICATIONS (2015)
The Centrosomal Linker and Microtubules Provide Dual Levels of Spatial Coordination of Centrosomes
Marko Panic et al.
PLOS GENETICS (2015)
Understanding Biology to Tackle the Disease: Multiple Myeloma From Bench to Bedside, and Back
Giada Bianchi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma
W. Zhou et al.
LEUKEMIA (2014)
Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells
Xin-Yan Pei et al.
PLOS ONE (2014)
NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
Ye Yang et al.
ONCOTARGET (2014)
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
Wen Zhou et al.
CANCER CELL (2013)
An allometric relationship between mitotic spindle width, spindle length, and ploidy in Caenorhabditis elegans embryos
Yuki Hara et al.
MOLECULAR BIOLOGY OF THE CELL (2013)
The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
Heather J. Landau et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2
Xin-Yan Pei et al.
BLOOD (2011)
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
Lijuan Chen et al.
BLOOD (2010)
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Annemiek Broyl et al.
BLOOD (2010)
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
Yuhuan Zheng et al.
BLOOD (2009)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
The forkhead-associated domain protein Cep170 interacts with polo-like kinase 1 and serves as a marker for mature centrioles
G Guarguaglini et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
Share Paper
